ATE209041T1 - Durch hla-b44 moleküle präsentierte tumor- abstossungsantigene und ihre verwendung - Google Patents

Durch hla-b44 moleküle präsentierte tumor- abstossungsantigene und ihre verwendung

Info

Publication number
ATE209041T1
ATE209041T1 AT96935876T AT96935876T ATE209041T1 AT E209041 T1 ATE209041 T1 AT E209041T1 AT 96935876 T AT96935876 T AT 96935876T AT 96935876 T AT96935876 T AT 96935876T AT E209041 T1 ATE209041 T1 AT E209041T1
Authority
AT
Austria
Prior art keywords
hla
tumor rejection
molecules
rejection antigens
antigens presented
Prior art date
Application number
AT96935876T
Other languages
English (en)
Inventor
Jean Herman
Pierre Coulie
Der Bruggen Pierre Van
Thierry Boon-Falleur
Original Assignee
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst Cancer Res filed Critical Ludwig Inst Cancer Res
Application granted granted Critical
Publication of ATE209041T1 publication Critical patent/ATE209041T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
AT96935876T 1995-09-21 1996-09-19 Durch hla-b44 moleküle präsentierte tumor- abstossungsantigene und ihre verwendung ATE209041T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/531,864 US5977300A (en) 1994-06-03 1995-09-21 Isolated nonapeptide which bind to HLA-B44 molecules and the uses thereof
PCT/US1996/015078 WO1997010837A1 (en) 1995-09-21 1996-09-19 Tumor rejection antigens presented by hla-b44 molecules, and uses thereof

Publications (1)

Publication Number Publication Date
ATE209041T1 true ATE209041T1 (de) 2001-12-15

Family

ID=24119368

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96935876T ATE209041T1 (de) 1995-09-21 1996-09-19 Durch hla-b44 moleküle präsentierte tumor- abstossungsantigene und ihre verwendung

Country Status (14)

Country Link
US (2) US5977300A (de)
EP (1) EP0854727B1 (de)
JP (1) JP3355360B2 (de)
CN (1) CN1119169C (de)
AT (1) ATE209041T1 (de)
AU (1) AU714884B2 (de)
CA (1) CA2232325C (de)
DE (1) DE69617255T2 (de)
DK (1) DK0854727T3 (de)
ES (1) ES2168514T3 (de)
NZ (1) NZ320837A (de)
PT (1) PT854727E (de)
TW (1) TW387899B (de)
WO (1) WO1997010837A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6060257A (en) * 1994-06-03 2000-05-09 Ludwig Institute For Cancer Research Tumor rejection antigens presented by HLA-B44 molecules, and uses thereof
EP1266221A1 (de) * 2000-01-20 2002-12-18 Ludwig Institute For Cancer Research An hla-b35 und hla-b44 bindende mage antigene peptide
US11945850B2 (en) 2018-09-17 2024-04-02 Immatics Biotechnologies Gmbh B*44 restricted peptides for use in immunotherapy against cancers and related methods

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5888512A (en) * 1987-01-30 1999-03-30 Board Of Trustees Of The Leland Stanford Junior University Lymphocyte activity regulation by HLA peptides
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
ES2225824T3 (es) * 1992-08-31 2005-03-16 Ludwig Institute For Cancer Research Nonapeptido aislado derivado del gen mage-3 y presentado por hla-a1, y sus usos.
US5405940A (en) * 1992-08-31 1995-04-11 Ludwig Institute For Cancer Research Isolated nonapeptides derived from MAGE genes and uses thereof
US5997870A (en) * 1994-06-03 1999-12-07 Ludwig Institute For Cancer Research Isolated peptides which bind to HLA-B44 Molecules
US6060257A (en) * 1994-06-03 2000-05-09 Ludwig Institute For Cancer Research Tumor rejection antigens presented by HLA-B44 molecules, and uses thereof

Also Published As

Publication number Publication date
CA2232325A1 (en) 1997-03-27
DK0854727T3 (da) 2002-02-25
AU714884B2 (en) 2000-01-13
DE69617255T2 (de) 2002-07-18
CN1119169C (zh) 2003-08-27
CN1197393A (zh) 1998-10-28
PT854727E (pt) 2002-05-31
US5977300A (en) 1999-11-02
EP0854727B1 (de) 2001-11-21
US6171806B1 (en) 2001-01-09
AU7365996A (en) 1997-04-09
TW387899B (en) 2000-04-21
JPH11509860A (ja) 1999-08-31
EP0854727A1 (de) 1998-07-29
DE69617255D1 (de) 2002-01-03
CA2232325C (en) 2007-01-09
HK1016482A1 (en) 1999-11-05
EP0854727A4 (de) 1999-08-18
WO1997010837A1 (en) 1997-03-27
ES2168514T3 (es) 2002-06-16
NZ320837A (en) 1999-02-25
JP3355360B2 (ja) 2002-12-09

Similar Documents

Publication Publication Date Title
EP0711173A4 (de) Isolierte peptide, die mit mhc mulekül hla-c-klon 10 komplexe bilden und ihre verwendungen
TR199801722T2 (xx) Peptit imm�nojenler.
EP0671927A4 (de) Menschliche, neutralisierende, monoklonale antikörper gegen das respiratorische synzytialviru.
MXPA02000119A (es) Elementos mezcladores estaticos apilados.
PT724456E (pt) Anticorpos contra cd4
ATE209680T1 (de) Isolierte nukleinsäuremoleküle, peptide die mit hla-a2 moleküle (mhc) komplexe bilden, sowie deren verwendungen
AU7690596A (en) Anti-CD6 monoclonal antibodies and their uses
TW200510459A (en) RG1 antibodies and uses thereof
NO965378D0 (no) Pyrazolo- og pyrolopyridiner
BR9809656A (pt) Composição imunopotencializante
GR3026219T3 (en) Mouse monoclonal antibodies
BG101024A (bg) Моноклонално антитяло срещу сd44v6
CA2093928A1 (en) Monoclonal antibodies for detection and treatment of cancer
ES2164914T3 (es) Medicamentos de inmunoterapia que contienen anticuerpos que detectan especificamente el antigeno mhcii del paciente a tratar.
FI963779A7 (fi) MAGE-kasvainhyljintäantigeeniprekursoreista saatuja eristettyjä peptid ejä, jotka kompleksoituvat HLA-A2-molekyylien kanssa
EP0350690A3 (de) Neutralisation der in vitro- und in vivo-toxischen Eigenschaften von TNF-alfa durch monoklonale Antikörper und die davon abgeleiteten Fragmente
DE59504707D1 (de) Arzneimittel für die verlängerte immunsuppression und tumorzellelimination
ATE239035T1 (de) Durch hla-b44 moleküle präsentierte tumor- abstossungsantigene und ihre verwendungen
NO952385D0 (no) Fremgangsmåte til identifisering av individer med unormale celler som uttrykker HLA-A2/tyrosinasepeptidantigen
IL187595A0 (en) Antitumor antibodies, proteins, and uses thereof
CA2184175A1 (en) Isolated, tyrosinase derived peptides and uses thereof
UY26266A1 (es) Antigeno asociado con tumores (r11) ley 17164
WO2001029220A3 (en) Mage-a12 antigenic peptides and uses thereof
PT948319E (pt) Celulas encapsuladas produtoras de anticorpos
EP0854727A4 (de) Durch hla-b44 moleküle präsentierte tumor-abstossungsantigene und ihre verwendung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0854727

Country of ref document: EP